TCPOBOP‐Induced Hepatomegaly and Hepatocyte Proliferation are Attenuated by Combined Disruption of MET and EGFR Signaling

Bharat Bhushan, John W. Stoops, Wendy M. Mars, Anne Orr, William C. Bowen, Shirish Paranjpe, George K. Michalopoulos – 11 June 2018 – TCPOBOP (1,4‐Bis [2‐(3,5‐Dichloropyridyloxy)] benzene) is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss. TCPOBOP‐induced direct hyperplasia has been considered to be CAR‐dependent with no evidence of involvement of cytokines or growth factor signaling.

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

Naim Alkhouri, Fred Poordad, Eric Lawitz – 7 June 2018 – Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with existing T2D. The diabetes spectrum includes several conditions from prediabetes to T2D to insulin‐dependent diabetes leading to macrovascular and microvascular complications.

Subscribe to